FIA
PRLD icon

FNY Investment Advisers’s Prelude Therapeutics PRLD Stock Holding History

FNY Investment Advisers’s Portfolio PRLD Stock Details PRLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-200
Closed -$1K – 689
2022
Q4 		$1K Buy
+200
New +$1.28K ﹤0.01% 460

Other funds holding PRLD

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

FNY Investment Advisers's PRLD Position: Q1 2023 in Review

FNY Investment Advisers sold out of Prelude Therapeutics (PRLD) in Q1 2023, closing a stake of 200 shares — an estimated $1K sold.

FNY Investment Advisers first reported a position in PRLD in Q4 2022 and held it in 1 quarter. The position peaked at $1K in Q4 2022. 54 funds tracked by Wall St. Rank hold PRLD as of Q1 2023.

  • FNY Investment Advisers reported no remaining Prelude Therapeutics position as of Q1 2023 after selling out during the quarter.
  • FNY Investment Advisers sold 200 Prelude Therapeutics shares in Q1 2023, an estimated $1K.
  • FNY Investment Advisers first reported a position in Prelude Therapeutics in Q4 2022 and held it in 1 quarter.
  • FNY Investment Advisers's Prelude Therapeutics position peaked at $1K in Q4 2022.
  • 54 funds tracked by Wall St. Rank held Prelude Therapeutics as of Q1 2023.

Based on FNY Investment Advisers's 13F filing for Q1 2023, filed 12 Apr 2023.